NCT06909877View on ClinicalTrials.gov

Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 27, 2022

Primary Completion Date

October 30, 2025

Study Completion Date

July 30, 2027

Conditions
Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Interventions
DRUG

HH2853 Tablets

25mg, 100mg and 200 mg BID oral administration

Trial Locations (1)

Unknown

RECRUITING

Sichuan Cancer Hospital, Chengdu

Sponsors
All Listed Sponsors
lead

Haihe Biopharma Co., Ltd.

INDUSTRY